Evaluation of the role of local therapy in patients with cN1M0 prostate cancer: A population-based study from the SEER database
暂无分享,去创建一个
Zicheng Xu | Xiao Li | Feng Qi | Wenbo Xu | Lu Li
[1] V. Khoo,et al. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. , 2022, JAMA oncology.
[2] F. Saad,et al. Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer , 2022, The Prostate.
[3] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[4] K. Bevans,et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. , 2021, The Lancet. Oncology.
[5] M. Cooperberg,et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. , 2021, JAMA oncology.
[6] Josephine M. E. Gibson,et al. Non-medical prescribing in primary care in the United Kingdom: an overview of the current literature , 2021, Journal of Prescribing Practice.
[7] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[8] U. Nagele,et al. Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. , 2021, European urology oncology.
[9] A. Jha,et al. Changes in Racial Disparities in Mortality After Cancer Surgery in the US, 2007-2016 , 2020, JAMA network open.
[10] H. Weir,et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.
[11] Y. Shioyama,et al. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? , 2020, Urologic oncology.
[12] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[13] Shailesh Singh,et al. Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer , 2019, Cancers.
[14] H. G. van der Poel,et al. Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature , 2019, BJU international.
[15] E. Antonarakis,et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.
[16] Ronald C. Chen,et al. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. , 2019, European urology oncology.
[17] J. Barentsz,et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. , 2019, European urology.
[18] A. Amini,et al. Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? , 2019, European urology.
[19] James D. Murphy,et al. Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. , 2019, European urology oncology.
[20] P. Meltzer,et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations , 2018, Journal of Immunotherapy for Cancer.
[21] Raj Persad,et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.
[22] James D. Murphy,et al. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.
[23] U. Haberkorn,et al. 68Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature , 2018, Clinical physiology and functional imaging.
[24] H. Weir,et al. Liver cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.
[25] C. B. Steele,et al. Prostate cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.
[26] A. Kural,et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[27] J. McKenney,et al. Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[28] M. Menon,et al. Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. , 2017, European urology.
[29] H. Brenner,et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? , 2017, BJU international.
[30] P. Stricker,et al. Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer , 2017, BJU international.
[31] H. Heinzer,et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.
[32] S. Hollinghurst,et al. Systematic review of the published literature , 2015 .
[33] A. Jemal,et al. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. , 2015, Journal of the National Cancer Institute.
[34] R. Kumar,et al. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. , 2015, Clinical nuclear medicine.
[35] E. Crawford,et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. , 2014, International journal of radiation oncology, biology, physics.
[36] J. Tward,et al. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. , 2013, Practical radiation oncology.
[37] A. Heidenreich,et al. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. , 2007, European urology.
[38] P. Malone,et al. Prostate , 1995 .
[39] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[40] A. Stenzl,et al. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. , 1990, The Journal of urology.